Investigational RCC agent improves progression-free survival ModernMedicine All 517 patients in the study had clear cell RCC, had undergone a prior nephrectomy, and had not previously been treated with either a vascular endothelial growth factor or mammalian target of rapamycin therapy. Among the study's key findings: ... |
